Targeted clinical trials

Designs for Clinical Trials: Perspectives on Current Issues

Volumn , Issue , 2012, Pages 157-177

  George, Stephen L ^a   Wang, Xiaofei ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013398288     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-0140-7_7     Document Type: Chapter

References (67)

1. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634
2. Bedard PL, de Azambuja E, Cardoso F (2009) Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Current Canc Drug Targets 9:148-162
3. Betensky RA, Louis DN, Cairncross JG (2002) Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20:2495-2499
4. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Therapeut 69:89-95
5. Bonetti M, Gelber RD (2000) A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19:2595-2609
6. Byar DP (1985) Assessing apparent treatment - covariate interactions in randomized clinical trials. Stat Med 4:255-263
7. Conley BA, Taube SE (2004) Prognostic and predictive markers in cancer. Dis Markers 20:35-43
8. Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ (2008) Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 26:848-855
9. Finn RS, Press M, Dering J, Platek G, Arbushites M, Johnston S (2009) Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008. J Clin Oncol 27:15s.
10. Freidlin B, Simon R (2005) Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Canc Res 11:7872-7878
11. Freidlin B, Korn EL, Gray R, Martin A (2008) Multi-arm clinical trials of new agents: Some design considerations. Clin Canc Res 14:4368-4371
12. Freidlin B, McShane LM, Korn EL (2010) Randomized clinical trials with biomarkers: Design issues. J Natl Canc Inst 102:152-160
13. George SL (1984) The required size and length of a clinical trial. In: Buyse ME, Staquet MJ, Sylvester RJ (eds) Cancer clinical trials. Oxford University Press, Oxford, pp 287-310
14. George SL (2008) Statistical issues in translational cancer research. Clin Canc Res 14:5954-5958
15. George SL (2010) Design of phase III clinical trials. In: Kelly WK, Halabi S (eds) Oncology clinical trials: Successful design, conduct and analysis. Demos Medical Publishing, New York, pp 83-91
16. George SL, Desu MM (1974) Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis 27:15-24
17. Gown AM (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Modern Pathol 21(Suppl 2):S8-S15
18. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast Jr RC (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312
19. Haq B, Geyer CE (2009) Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer. Women's Health 5:135-147
20. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ (1996) Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. JNCI J Natl Canc Inst 88:1456-1466
21. Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK (letter). Breast Canc Res Treatment 100:237-238
22. Hoering A, LeBlanc M, Crowley JJ (2008) Randomized phase III clinical trial designs for targeted agents. Clin Canc Res 14:4358-4367
23. Hudis CA (2007) Trastuzumab - Mechanism of action and use in clinical practice. New Engl J Med 357:39-51
24. Jiang W, Freidlin B, Simon R (2007) Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Canc Inst 99:1036-1043
25. Jordan VC (2006) Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Brit J Pharmacol 147(Suppl 1):S269-S276
26. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med 359:1757-1765
27. Lee CK, Lord SJ, Coates AS, Simes RJ (2009) Molecular biomarkers to individualise treatment: Assessing the evidence. Med J Aust 190:631-636
28. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast Jr RC (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327
29. Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H (2008) Adjuvant/ neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Canc Treatment Rev 34:539-557
30. Maitournam A, Simon R (2005) On the efficiency of targeted clinical trials. Stat Med 24:329-339
31. Mandrekar SJ, Sargent DJ (2009a) Clinical trial designs for predictive biomarker validation: One size does not fit all. J Biopharmaceut Stat 19:530-542
32. Mandrekar SJ, Sargent DJ (2009b) Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 27:4027-4034
33. Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ (2005) Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics 5:317-325
34. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, For the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). JNCI J Natl Canc Inst 97:1180-1184
35. Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG (2009) Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 27:2022-2029
36. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. New Engl J Med 361:947-957
37. Paik S, Kim C, Wolmark N (2008) HER2 status and benefit from adjuvant trastuzumab in breast cancer (letter). New Engl J Med 358:1409-1411
38. Palta M, Amini SB (1985) Consideration of covariates and stratification in sample size determination for survival time studies. J Chronic Dis 38:801-809
39. Pepe MS (2005) Evaluating technologies for classification and prediction in medicine. Stat Med 24:3687-3696
40. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M,Winget M, Yasui Y, (2001) Phases of biomarker development for early detection of cancer. J Natl Canc Inst 93:1054-1061
41. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Canc Inst 100:1432-1438
42. Peterson B, George SL (1993) Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome. Contr Clin Trials 14:511-522
43. Ransohoff DF (2007) How to improve reliability and efficiency of research about molecular markers: Roles of phases, guidelines, and study design. J Clin Epidemiol 60:1205-1219
44. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 353:1673-1684
45. Royston P, Sauerbrei W (2004) A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. StatMed 23:2509-2525
46. Sargent D, Allegra C (2002) Issues in clinical trial design for tumor marker studies. Seminars Oncol 29:222-230
47. Sargent DJ, Conley BA, Allegra C, Collette L (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020-2027
48. Schoenfeld D (1981) The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 68:316-319
49. Simon R (2005a) Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Canc Inst 97:866-867
50. Simon R (2005b) Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23:7332-7341
51. Simon R (2008a) Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics. Expert Opin Med Diagn 2:721-729
52. Simon R (2008b) The use of genomics in clinical trial design. Clin Canc Res 14:5984-5993
53. Simon R, Maitournam A (2004) Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Canc Res 10:6759-6763
54. Simon R,Wang SJ (2006) Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics J 6:166-173
55. Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Canc Inst 101:1446-1452
56. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl JMed 344:783-792
57. Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI (2009) A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. JNCI J Natl Canc Inst 101:1453-1463
58. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lorente P (2009) Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in firstline human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27:18s
59. Vittinghoff E, Bauer DC (2006) Case-only analysis of treatment-covariate interactions in clinical trials. Biometrics 62:769-776
60. Vroling L, Lind JSW, de Haas RR, Verheul HMW, van Hinsbergh VWM, Broxterman HJ, Smit EF (2009) CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Canc 102:268-275
61. Wang X, Zhou H (2010) Design and inference for cancer biomarker study with an outcome and auxiliary-dependent subsampling. Biometrics 66:502-511
62. Wang SJ, O'Neill RT, Hung HMJ (2007) Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceut Stat 6:227-244
63. Wang X, Pang H, Schwartz TA (2009) Building and validating high throughput lung cancer biomarkers. Chance 22:55-62
64. Xiangwei M, Jian G, Xinzheng W (2003) Order statistics for negative exponential distribution and its applications. IEEE International Conference Neural Networks and Signal Processing, pp 720-722
65. Yamamoto H, Toyooka S, Mitsudomi T (2009) Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Canc 63:315-321
66. Zhang B, Li Y, Betensky RA (2006) Effects of unmeasured heterogeneity in the linear transformation model for censored data [Erratum appears in Lifetime Data Anal. 2007 Sep 13(3):431]. Lifetime Data Anal 12:191-203
67. Zhou X, Liu SY, Kim ES, Herbst RS, Lee JL (2008) Bayesian adaptive design for targeted therapy development in lung cancer - a step toward personalized medicine. Clin Trials 5:181-193